Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 575 of 591 entries
View as:

Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT03440567 Org: User:
Start: 04/02/18 End: 06/26/24 Due: 06/26/25

Influenza Vaccine in Preventing Flu in Patients Who Have Undergone Stem Cell Transplant and in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT00952185 Org: User:
Start: 11/30/08 End: 06/30/10 Due: 06/30/11

Effects of a Teaching Intervention With an Advanced Practice Nurse on Quality of Life and Psychosocial and Symptom Distress in Patients With Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00900679 Org: User:
Start: 07/31/08 End: 02/28/10 Due: 02/28/11

Electron Beam Radiotherapy for the Treatment of Refractory Sclerodermatous Chronic Graft Versus Host Disease

Phase: N/A Priority: Normal
NCT ID: NCT05515692 Org: User:
Start: 06/30/24 End: 09/18/24 Due: 09/18/25

Validation of an RLIP76 Assay in Humans

Phase: N/A Priority: Normal
NCT ID: NCT01824017 Org: User:
Start: 12/31/12 End: 09/30/16 Due: 09/30/17

Genetic Testing in Predicting Biomarkers of Recurrence in Patients With Prostate Cancer Undergoing Surgery

Phase: N/A Priority: Normal
NCT ID: NCT00977457 Org: User:
Start: 11/26/07 End: 07/10/25 Due: 07/10/26

Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor

Phase: N/A Priority: Normal
NCT ID: NCT06572631 Org: User:
Start: 06/07/25 End: 12/12/26 Due: 12/12/27

An Immunotherapy Vaccine (PIpepTolDC) for the Treatment of Patients With Type 1 Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT04590872 Org: User:
Start: 06/16/22 End: 06/10/25 Due: 06/10/26

Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT04484012 Org: User:
Start: 12/31/20 End: 09/02/25 Due: 09/02/26

Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02778685 Org: User:
Start: 09/30/16 End: 03/30/26 Due: 03/30/27

Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy

Phase: N/A Priority: Normal
NCT ID: NCT03671811 Org: User:
Start: 01/21/19 End: 03/30/26 Due: 03/30/27

Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02648477 Org: User:
Start: 03/28/16 End: 12/30/23 Due: 12/30/24

Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR)

Phase: N/A Priority: Normal
NCT ID: NCT05371132 Org: User:
Start: 06/20/22 End: 10/05/26 Due: 10/05/27

Immunoscintigraphy Using Radiolabeled Monoclonal Antibody in Finding Tumor Cells in Patients With Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00647153 Org: User:
Start: 05/31/06 End: 10/31/12 Due: 10/31/13

Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT06859008 Org: User:
Start: 02/07/26 End: 01/28/28 Due: 01/28/29

A Blood Stem Cell Transplant for Sickle Cell Disease

Phase: N/A Priority: Normal
NCT ID: NCT03249831 Org: User:
Start: 01/04/19 End: 02/18/26 Due: 02/18/27

Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study

Phase: N/A Priority: Normal
NCT ID: NCT05718869 Org: User:
Start: 05/18/23 End: 10/19/25 Due: 10/19/26

Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT01961063 Org: User:
Start: 12/31/15 End: 08/28/25 Due: 08/28/26

MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02041481 Org: User:
Start: 06/30/14 End: 01/19/18 Due: 01/19/19

Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00004092 Org: User:
Start: 05/31/99 End: 12/31/13 Due: 12/31/14

Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study

Phase: N/A Priority: Normal
NCT ID: NCT06052826 Org: User:
Start: 06/23/23 End: 10/05/26 Due: 10/05/27

Survivorship Care Planning in Improving the Quality of Life in Breast Cancer Survivors

Phase: N/A Priority: Normal
NCT ID: NCT01824745 Org: User:
Start: 07/15/13 End: 06/15/25 Due: 06/15/26

Actinium 225 Labeled Anti-CEA Antibody (Ac225-DOTA-M5A) for the Treatment of CEA Producing Advanced or Metastatic Cancers

Phase: N/A Priority: Normal
NCT ID: NCT05204147 Org: User:
Start: 06/02/22 End: 08/07/25 Due: 08/07/26

Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant

Phase: N/A Priority: Normal
NCT ID: NCT06543381 Org: User:
Start: 01/17/25 End: 02/05/27 Due: 02/05/28

90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT05139004 Org: User:
Start: 07/19/22 End: 06/13/27 Due: 06/13/28